Kadimastem Ltd (KMSTF)
USD 0.64
(-90.0%)
USD 0.64
(-90.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.41 Million USD | -57.74% |
| 2022 | 5.7 Million USD | -21.06% |
| 2021 | 7.22 Million USD | 25.61% |
| 2020 | 5.75 Million USD | -15.92% |
| 2019 | 6.84 Million USD | -2.43% |
| 2018 | 7.01 Million ILS | 16.98% |
| 2017 | 5.99 Million ILS | 14.3% |
| 2016 | 5.24 Million ILS | -67.91% |
| 2015 | 16.34 Million ILS | 3.22% |
| 2014 | 15.83 Million ILS | 3.56% |
| 2013 | 15.28 Million ILS | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 Q2 | 1.43 Million USD | 0.0% |
| 2023 Q4 | 944.93 Thousand USD | 0.0% |
| 2023 FY | 2.41 Million USD | -57.74% |
| 2022 FY | 5.7 Million USD | -21.06% |
| 2022 Q2 | 3.18 Million USD | 0.0% |
| 2022 Q4 | 2.53 Million USD | 0.0% |
| 2021 Q2 | 3.67 Million USD | 0.0% |
| 2021 FY | 7.22 Million USD | 25.61% |
| 2021 Q4 | 3.36 Million USD | 0.0% |
| 2020 Q2 | 3 Million ILS | -50.73% |
| 2020 Q1 | 6.1 Million ILS | 79.28% |
| 2020 Q4 | 2.5 Million USD | 0.0% |
| 2020 FY | 5.75 Million USD | -15.92% |
| 2019 FY | 6.84 Million USD | -2.43% |
| 2019 Q4 | 3.4 Million USD | 0.0% |
| 2019 Q2 | 3.32 Million USD | 0.0% |
| 2018 FY | 7.01 Million ILS | 16.98% |
| 2017 FY | 5.99 Million ILS | 14.3% |
| 2016 FY | 5.24 Million ILS | -67.91% |
| 2015 FY | 16.34 Million ILS | 3.22% |
| 2014 FY | 15.83 Million ILS | 3.56% |
| 2013 FY | 15.28 Million ILS | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -80.474% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 52.2% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 91.845% |
| Nascent Biotech, Inc. | 2.22 Million USD | -8.083% |
| Rebus Holdings, Inc. | 664 Thousand USD | -262.969% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 93.531% |
| Qrons Inc. | 643.67 Thousand USD | -274.429% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -518.666% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 95.804% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -480.08% |
| Skye Bioscience, Inc. | 13.54 Million USD | 82.21% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 97.223% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 50.993% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -820.853% |
| SQZ Biotechnologies Company | 85.61 Million USD | 97.185% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 17.355% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -60.471% |
| Mesoblast Limited | 5.9 Million USD | 59.164% |
| Marizyme, Inc. | 19.23 Million USD | 87.473% |
| Genus plc | 147.7 Million USD | 98.368% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 72.548% |
| Pharming Group N.V. | 225.49 Million USD | 98.931% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -17.641% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -79.652% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 71.098% |
| ContraFect Corporation | 56.88 Million USD | 95.763% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 45.332% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -62.983% |
| IMV Inc. | 37.7 Million USD | 93.609% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 13.627% |
| MultiCell Technologies, Inc. | 567.42 USD | -424649.216% |
| ONE Bio Corp. | 6.44 Million USD | 62.599% |
| Accustem Sciences Inc. | 3.74 Million USD | 35.669% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 97.196% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -353.061% |
| Q BioMed Inc. | 3.43 Million USD | 29.87% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 90.248% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 8.274% |
| Biomind Labs Inc. | 994.18 Thousand USD | -142.422% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 97.574% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -36.963% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 64.125% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -29.272% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 9740.448% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 84.946% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -31.334% |
| GB Sciences, Inc. | 1.42 Million USD | -69.665% |
| Alpha Cognition Inc. | 9.7 Million USD | 75.168% |
| HST Global, Inc. | 140.9 Thousand USD | -1610.427% |
| CSL Limited | 3.44 Billion USD | 99.93% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -114.249% |
| Halberd Corporation | 74.84 Thousand USD | -3120.267% |
| Enzolytics Inc. | 2.17 Million USD | -10.581% |
| Agentix Corp. | 1.37 Million USD | -75.695% |
| Resverlogix Corp. | 12.71 Million USD | 81.041% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 33.982% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.843% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -130.854% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -0.215% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -52.601% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 29.218% |
| AVAX Technologies, Inc. | 7.31 Million USD | 67.031% |
| Zenith Capital Corp. | 8.94 Million USD | 73.05% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.708% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -13734.522% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 1.841% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1305.239% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -25.467% |
| Helix BioMedix, Inc. | 1.97 Million USD | -22.215% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 77.822% |
| BioStem Technologies, Inc. | 22.97 Million USD | 89.51% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1227.995% |
| LadRx Corporation | 3.81 Million USD | 36.772% |
| Cell Source, Inc. | 4.32 Million USD | 44.279% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -160.973% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -160.973% |
| NovAccess Global Inc. | 2.46 Million USD | 2.296% |
| Affymax, Inc. | 39.38 Million USD | 93.881% |
| Itoco Inc. | 919.14 Thousand USD | -162.213% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 43.136% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -115.381% |
| Mobile Lads Corp. | 554.54 Thousand USD | -334.61% |
| CytoDyn Inc. | 18.05 Million USD | 86.653% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -9475.716% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -995.117% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -69.751% |
| SYBLEU INC | 160.87 Thousand USD | -1398.118% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -32.692% |
| International Stem Cell Corporation | 5.27 Million USD | 54.276% |
| Bioxytran, Inc. | 3.82 Million USD | 36.91% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -4478.306% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -11747.377% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 93.354% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -48.956% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -227.534% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 22.529% |
| Neutra Corp. | 243.82 Thousand USD | -888.476% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 86.194% |
| PureTech Health plc | 144.59 Million USD | 98.333% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 88.238% |
| IXICO plc | 4.7 Million USD | 48.797% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 72.603% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 97.953% |
| CSL Limited | 3.89 Billion USD | 99.938% |
| Cellectis S.A. | 97.32 Million USD | 97.524% |